Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial-Reference-Cited by-同舟云学术

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Published:2017-11 Issue:10107 Volume:390 Page:2073-2082
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Sax Paul E,Pozniak Anton,Montes M Luisa,Koenig Ellen,DeJesus Edwin,Stellbrink Hans-Jürgen,Antinori Andrea,Workowski Kimberly,Slim Jihad,Reynes Jacques,Garner Will,Custodio Joseph,White Kirsten,SenGupta Devi,Cheng Andrew,Quirk Erin

Publisher

Elsevier BV

Subject

General Medicine

Reference19 articles.

1. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society—USA Panel;Gunthard;JAMA,2016

2. Guidelines,2015

3. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial;Lennox;Ann Intern Med,2014

4. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection;Walmsley;N Engl J Med,2013

5. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study;Clotet;Lancet,2014

Cited by 240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of pretreatment HIV drug resistance testing in people living with HIV in Iran;PLOS ONE;2024-09-06

2. Switching Human Immunodeficiency Virus Therapy;Infectious Disease Clinics of North America;2024-09

3. Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines;Cell Reports Medicine;2024-08

4. Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study;Journal of Antimicrobial Chemotherapy;2024-07-24

5. Challenges for Novel Antiretroviral Development in an Era of Widespread tenofovir-disoproxil/lamivudine (or emtricitabine)/dolutegravir availability (TLD) Availability;Clinical Infectious Diseases;2024-07-11